A new trading day began on Tuesday, with Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) stock price up 8.58% from the previous day of trading, before settling in for the closing price of $15.16. CNTA’s price has ranged from $7.38 to $18.97 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 2.97%. With a float of $90.14 million, this company’s outstanding shares have now reached $131.66 million.
Let’s determine the extent of company efficiency that accounts for 76 employees. In terms of profitability, gross margin is 89.52%, operating margin of -2342.65%, and the pretax margin is -2294.59%.
Centessa Pharmaceuticals plc ADR (CNTA) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Centessa Pharmaceuticals plc ADR is 31.53%, while institutional ownership is 51.06%. The most recent insider transaction that took place on Jan 21 ’25, was worth 840,950. Before that another transaction happened on Jan 15 ’25, when Company’s General Counsel sold 6,000 for $15.29, making the entire transaction worth $91,740. This insider now owns 118,265 shares in total.
Centessa Pharmaceuticals plc ADR (CNTA) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 2.97% per share during the next fiscal year.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Trading Performance Indicators
Here are Centessa Pharmaceuticals plc ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 21.52. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 313.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.55 in one year’s time.
Technical Analysis of Centessa Pharmaceuticals plc ADR (CNTA)
Looking closely at Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA), its last 5-days average volume was 0.42 million, which is a drop from its year-to-date volume of 0.54 million. As of the previous 9 days, the stock’s Stochastic %D was 35.93%. Additionally, its Average True Range was 1.14.
During the past 100 days, Centessa Pharmaceuticals plc ADR’s (CNTA) raw stochastic average was set at 58.37%, which indicates a significant increase from 56.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.70% in the past 14 days, which was higher than the 60.73% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.83, while its 200-day Moving Average is $13.00. However, in the short run, Centessa Pharmaceuticals plc ADR’s stock first resistance to watch stands at $17.08. Second resistance stands at $17.70. The third major resistance level sits at $18.76. If the price goes on to break the first support level at $15.40, it is likely to go to the next support level at $14.34. Now, if the price goes above the second support level, the third support stands at $13.72.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Key Stats
With a market capitalization of 2.17 billion, the company has a total of 131,845K Shares Outstanding. Currently, annual sales are 6,850 K while annual income is -151,090 K. The company’s previous quarter sales were 0 K while its latest quarter income was -42,570 K.
